SCHEDULE 13G/A: Bristol-Myers Squibb Discloses 2.06% Passive Stake in Compugen Ltd.

Bristol-Myers Squibb Company has filed an amended Schedule 13G, reporting a 2.06% passive beneficial ownership stake in Compugen Ltd. as of December 31, 2024.

Summary

• Bristol-Myers Squibb Company (BMS) filed an Amendment No. 1 to Schedule 13G regarding its beneficial ownership in Compugen Ltd.
• As of December 31, 2024, BMS beneficially owns 1,840,136 Ordinary Shares of Compugen Ltd.
• This ownership represents 2.06% of Compugen Ltd.'s outstanding Ordinary Shares.
• The percentage is calculated based on 89,237,465 Ordinary Shares of Compugen Ltd. that were outstanding as of June 30, 2024.
• BMS holds sole voting power and sole dispositive power over all 1,840,136 shares.
• The filing certifies that the shares were not acquired and are not held for the purpose of changing or influencing the control of Compugen Ltd.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. It's a routine disclosure of a passive stake by a significant industry player, indicating continued, albeit small, investment. No negative news, but also no major positive strategic developments.

Positives

• Indicates continued investment by a major pharmaceutical company (Bristol-Myers Squibb) in Compugen Ltd.
• The passive nature of the stake suggests a long-term investment perspective rather than an activist intent, which can be viewed positively by management.

Negatives

• The stake is below the 5% threshold, meaning it's a relatively small position for BMS and does not indicate a significant strategic shift or increased influence.
• No new strategic partnership or increased stake beyond what might have been previously reported (as this is an amendment, but the prior stake is not detailed in this document).

Future Outlook

The document is a Schedule 13G filing, which reports passive beneficial ownership and does not contain forward-looking statements or guidance regarding future operations or financial performance of either entity.

Management Comments

• The filing includes a certification by Bristol-Myers Squibb Company that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of Compugen Ltd.

Industry Context

This filing indicates a continued, passive investment by a major pharmaceutical company, Bristol-Myers Squibb, in a biotechnology firm, Compugen Ltd. Such passive stakes are common in the pharmaceutical and biotech sectors, often stemming from prior collaborations, strategic investments, or simply portfolio diversification, without implying direct operational influence or a new strategic partnership.

Comparison to Industry Standards

• As a passive ownership disclosure, this filing does not provide performance metrics for direct comparison to industry standards.
• A 2.06% stake is a minority position, typical for institutional investors or strategic partners who do not seek control. For instance, large pharmaceutical companies often hold small equity stakes in smaller biotech firms with whom they have research collaborations or licensing agreements, such as Pfizer's historical investments in various biotech startups or Merck's venture capital arm investing in emerging biotechs.
• Without specific financial or operational data from Compugen Ltd. in this document, a direct performance comparison is not feasible.

Stakeholder Impact

• Shareholders of Compugen Ltd. may view Bristol-Myers Squibb's continued passive stake as a sign of confidence, though the small percentage limits its direct impact on share price.
• Employees, customers, suppliers, and creditors are unlikely to be directly impacted by this passive ownership disclosure, as it does not signal operational changes or new strategic initiatives.

Next Steps

• The document does not specify any future actions, events, or milestones for either Bristol-Myers Squibb Company or Compugen Ltd. beyond the filing itself.

Key Dates

Recommendation

Keywords

Compugen Ltd., Bristol-Myers Squibb Company, Schedule 13G, Beneficial Ownership, Ordinary Shares, Passive Investment, SEC Filing, Biotechnology, Pharmaceuticals